US · FOLD · BIOTECHNOLOGY
Amicus Therapeutics, Inc. (FOLD) intrinsic value and stock valuation
$14.49as of 2026-04-27 · Mkt cap 4.51B
Data updated · price as of 2026-04-27
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Amicus Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values FOLD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FOLD’s statements →
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cidara Therapeutics, Inc. (CDTX) $221.38
- Scholar Rock Holding Corporation (SRRK) $44.27
- Arcutis Biotherapeutics, Inc. (ARQT) $26.97
- Kiniksa Pharmaceuticals, Ltd. (KNSA) $44.49
- Tarsus Pharmaceuticals, Inc. (TARS) $75.52
- Catalyst Pharmaceuticals, Inc. (CPRX) $23.08
- IDEAYA Biosciences, Inc. (IDYA) $32.20
- Adaptive Biotechnologies Corporation (ADPT) $16.02
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
- CEO
- Bradley L. Campbell
- Employees
- 499
- Beta
- 0.43
Explore
Frequently asked questions
What is the intrinsic value of Amicus Therapeutics, Inc. (FOLD)?
InvestorsCraft does not currently publish an intrinsic value for FOLD. How the IC value is calculated.
Is FOLD undervalued?
InvestorsCraft does not publish an undervaluation signal for FOLD at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Aug 18, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.